KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics^® discovery platform to achieve higher probabilities of success in drug development, announced today that KSQ CEO David Meeker, M.D., will present at the Piper Jaffray 31^st Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:30 a.m. ET in New York. Dr. Meeker will provide a corporate overview and update on the company's research and development programs in immuno-oncology and adoptive cell therapies.

The company has declared its lead program, a first-in-class biomarker-enabled monotherapy inhibitor of TO-4, an undisclosed target in the DNA Damage Repair (DDR) pathway, which the company plans to develop for ovarian cancer and triple negative breast cancer. The small molecule candidate has shown activity in certain BRCA-mutant and homologous recombination deficient (HRD) cancer models. The company's second program is KSQ-001, part of KSQ's engineered tumor-infiltrating lymphocyte (eTILtm) adoptive cell therapy program, which will be developed for the treatment of PD-1 refractory solid tumors.

"Over the past year, we have made significant progress in driving the translational process for the lead programs identified from our proprietary CRISPRomics discovery engine and advancing them toward development-stage programs," said Dr. Meeker. "Our focus for the year ahead will be on preparing the clinical program for our lead immuno-oncology candidate and initiating IND-enabling studies for our first adoptive cell therapy candidate. We have a high degree of confidence in the potential of both of these programs because of the insights that we generated that led to their discovery and the significant medical need in the therapeutic areas that we are pursuing."

About KSQ Therapeutics

KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ's proprietary CRISPRomics^® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.